[1] VAN DER PIJL E,VAN PUTTEN M,NIKS E,et al. Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice[J]. Neuromuscul Disord,2018,28(5):427
[2] TUFFERY-GIRAUD S,MIRO J,KOENIG M,et al. Normal and altered pre-mRNA processing in the DMD gene[J]. Hum Genet,2017, 136(9):1155
[3] GUIRAUD S,AARTSMA-RUS A,VIEIRA N,et al. The pathogenesis and therapy of muscular dystrophies[J]. Annu Rev Genomics Hum Genet,2015,16:281
[4] 卜鑫珏,奚鑫,刘松青,等. 治疗杜兴肌肉萎缩症的新药及其开发[J]. 中国新药杂志,2020,29(2):165
[5] MATTHEWS E,BRASSINGTON R,KUNTZER T,et al. Corticosteroids for the treatment of Duchenne muscular dystrophy[J]. Cocharne Db Syst Rev,2016(5):CD003725
[6] PEVERELLI L,TESTOLIN S,VILLA L,et al. Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy[J]. Neurology,2015,85(21):1886
[7] HEIER C,DAMSKER J,YU Q,et al. VBP15,a novel anti-inflammatory and membrane-stabilizer,improves muscular dystrophy without side effects[J]. EMBO Mol Med,2013,5(10):1569
[8] LIM K,MARUYAMA R,YOKOTA T. Eteplirsen in the treatment of Duchenne muscular dystrophy[J]. Drug Des Devel Ther,2017,11:533
[9] CIRAK S,ARECHAVALA-GOMEZA V,GUGLIERI M,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment:an open-label,phase 2,dose-escalation study[J]. Lancet,2011,378(9791):595
[10] HU Y,WU B,ZILLMER A,et al. Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo[J]. Mol Ther,2010,18(4):812
[11] KENDALL G,MOKHONOVA E,Moran M,et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy[J]. Sci Transl Med,2012,4(164):164
[12] HAN G,GU B,CAO L,et al. Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice[J]. Nat Commun,2016,7:1098
[13] LIN C,HAN G,NING H,et al. Glycine eenhances satellite cell proliferation,cell transplantation,and oligonucleotide efficacy in dystrophic muscle[J]. Mol Ther,2020,28(5):1339
[14] CHAWLA J,KVARNBERG D. Hydrosoluble vitamins[J]. Handb Clin Neurol,2014,120:891
[15] RAHIMOV F,KUNKEL L. The cell biology of disease:cellular and molecular mechanisms underlying muscular dystrophy[J]. J Cell Biol,2013,201(4):499
[16] KLEIN S,PRANTL L,GEIS S,et al. Circulating serum CK level vs. muscle impairment for in situ monitoring burden of disease in mdx-mice[J]. Clin Hemorheol Microcirc,2017,65(4):327
[17] LEWON M,PETERS C,VAN RY P,et al. Evaluation of the behavioral characteristics of the mdx mouse model of Duchenne muscular dystrophy through operant conditioning procedures[J]. Behav Processes,2017,142:8
[18] STEIN C. Eteplirsen approved for Duchenne muscular dystrophy:the FDA faces a difficult choice[J]. Mol Ther,2016,24(11):1884
[19] ANWAR S,YOKOTA T. Golodirsen for Duchenne muscular dystrophy[J]. Drugs Today (Barc),2020,56(8):491
[20] 宁含含,顾犇,韩刚,等. 己糖对杜兴肌肉萎缩症核酸药物Pip5e-PMO跳读活性研究[J]. 天津医科大学学报,2019,25(3):215
[21] VOLKOV I,PRESS Y,RUDOY I. Vitamin B12 could be a "master key" in the regulation of multiple pathological processes[J]. J Nippon Med Sch,2006,73(2):65
[22] ERFANPARAST A,Escort M,Tamaddonfard E,et al. Systemic and local peripheral injections of vitamin B12 suppressed orofacial nociception induced by formalin in rats[J]. Drug Res,2014,64(2):85
[1]宁含含,顾 犇,韩 刚,等.己糖对杜兴肌肉萎缩症核酸药物Pip5e-PMO跳读活性研究[J].天津医科大学学报,2019,25(03):215.
NING Han-han,GU Ben,HAN Gang,et al.Effect of hexoses on Pip5e-PMO mediated exon-skipping in the Duchenne muscular dystrophy mouse model[J].Journal of Tianjin Medical University,2019,25(05):215.
[2]钟丽,宋军,栗瑞斌,等.负载泼尼松龙牛奶外泌体治疗杜兴肌肉萎缩症的研究[J].天津医科大学学报,2024,30(03):218.[doi:10.20135/j.issn.1006-8147.2024.03.0218]
ZHONG Li,SONG Jun,LI Ruibin,et al.Study on the treatment of Duchenne muscular dystrophy with prednisolone loaded on milk exosomes[J].Journal of Tianjin Medical University,2024,30(05):218.[doi:10.20135/j.issn.1006-8147.2024.03.0218]